Physician

Eyal Konstantin Levit, M.D.

According to 2025 Medicare claims, Eyal Levit, M.D. (NPI: 1801813621) practices dermatology in the New York-Jersey City-White Plains, NY-NJ market, with the plurality of this provider's patient population coming from Kings, NY. This provider's primary affiliated billing organization is ADVANCED DERMATOLOGY LASER AND COSMETIC SURGERY P.C. (NPI: 1811032196; TIN: 201193081) and primary practice location at 11235-4870.

Levit's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 2,183 traditional Medicare patients, billed 25,912 HCPCS/CPT codes, and received $1,637,804 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 9,525 prescription claims across 1,830 beneficiaries totaling $4,346,461 in drug costs, led by Skyrizi Pen (Risankizumab-Rzaa). 2021 DME data shows 12 claims. Open Payments data shows 108 records totaling $7,020. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $694,768 to $1,637,804. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,080,113 to $4,346,461. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,041	6,785	$694,768
2016	1,015	6,841	$676,348
2017	1,301	8,677	$882,654
2018	1,689	12,390	$1,226,345
2019	1,696	12,894	$1,110,917
2020	1,378	9,274	$871,282
2021	1,422	8,527	$955,960
2022	1,738	14,334	$1,113,923
2023	2,169	28,004	$1,659,163
2024	2,183	25,912	$1,637,804

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	959	4,098	$1,080,113
2016	1,074	4,831	$1,364,308
2017	1,250	5,668	$1,959,054
2018	1,439	7,091	$2,059,172
2019	1,523	7,661	$2,487,718
2020	1,294	6,926	$2,739,363
2021	1,246	5,681	$3,017,501
2022	1,322	6,274	$4,142,307
2023	1,596	8,966	$5,126,397
2024	1,830	9,525	$4,346,461

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	12	$33
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	603	818	$118
11102	Biopsy of related skin growth, first growth	819	1,099	$87
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	1,372	3,132	$85
17000	Destruction of precancer skin growth, 1 growth	746	1,252	$53
17003	Destruction of precancer skin growth, 2-14 growths	589	5,246	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Skyrizi Pen	Risankizumab-Rzaa	37	2,834	$755,762
Opzelura	Ruxolitinib Phosphate	339	10,185	$670,472
Erivedge	Vismodegib	38	1,066	$508,757
Dupixent Pen	Dupilumab	136	3,752	$504,060
Tremfya	Guselkumab	24	1,344	$320,174

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	108	$7,020	Dermavant Sciences, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Eyal Konstantin Levit, M.D.?

Tedicare shows public-source Medicare data for Eyal Konstantin Levit, M.D. (NPI 1801813621), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Eyal Konstantin Levit, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Eyal Konstantin Levit, M.D.?

Eyal Konstantin Levit, M.D. is linked to ADVANCED DERMATOLOGY LASER AND COSMETIC SURGERY P.C. (billing NPI 1811032196) in the available physician profile data.

Does Eyal Konstantin Levit, M.D. have Open Payments data?

Eyal Konstantin Levit, M.D. has 108 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.